v3.26.3
REVENUE RECOGNITION
9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION

NOTE 5 – REVENUE RECOGNITION

 

The Company’s sources of revenue is product revenue from the sale of pharmaceutical products through wholesale distribution channels and from customers purchasing directly from the Company. ARBLI™ (SCN-102, Losartan Potassium Oral Suspension) received FDA approval in March 2025 and commenced commercialization in the fourth quarter of 2025. REZENOPY™ (SCN-110, naloxone HCl nasal spray, 10 mg) commenced commercial sales during the three months ended September 30, 2026. Revenue is recognized when control transfers to the wholesale distributor, generally upon delivery.

 

Revenue from sales to the wholesale distribution channel is measured at the net transaction price equal to the gross invoice price reduced by estimated variable consideration. Gross-to-net adjustments include:

 

Chargebacks. The difference between the invoice price charged to wholesale distributors and the lower contract price distributors extend to end-customers (retail pharmacies, hospitals, clinics). Estimated based on expected sell-through and contractual terms.

 

Wholesaler Rebates and Distribution Service Fees. Fees and rebates paid to wholesale distributors and group purchasing organizations under contractual arrangements. Estimated based on contracted rates and expected sales volumes.

 

Prompt Pay Discounts. Discounts offered to wholesale distributors for timely payment, estimated based on contractual terms.

 

Product Returns. Returns accepted under limited conditions (generally damaged, expired, or defective product). Returns have not been material to date given the early stage of ARBLI™ and REZENOPY™ commercialization.

 

Revenue from sales to direct customers are at the transaction price.

 

Estimates of variable consideration are reassessed each reporting period. Changes in estimates are recorded as adjustments to revenue in the period identified. Accrued gross-to-net liabilities are included within accrued liabilities on the consolidated balance sheets.

 

Revenue disaggregated by product for the three and nine months ended September 30, 2026 and 2025 is as follows:

 

Product            
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
Product  2026   2025   2026   2025 
ARBLI™ (SCN-102, Losartan Potassium Oral Suspension)  $329,783   $-   $729,747   $- 
REZENOPY™ (naloxone HCl nasal spray, 10 mg)   924,794    -    924,794    - 
Pharmaceutical product resale   -    590,050    -    600,308 
Total revenues  $1,254,577   $590,050   $1,654,541   $600,308